News

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.
Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.
GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...
A new study found weight loss injections may help reduce the risk of dementia and stroke in people who are obese and have type 2 diabetes ...
In a nutshell People with type 2 diabetes taking semaglutide (Ozempic/Wegovy) showed up to 46% lower dementia risk compared to those on other diabetes medications The protective effects were ...
The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School of Medicine suggests.
Weight loss jabs such as Wegovy and Mounjaro may offer a protective effect against dementia and stroke, according to a new study.
THEY’VE been hailed as miracle weight-loss jabs – but the effects of Ozempic-style drugs could go far beyond the waistline. New research suggests these so-called “skinny pens” may also ...
Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious conditions such as dementia and stroke, a new study has indicated. The research ...
A new study involving nearly 1.7 million patients suggests that semaglutide — a drug that mimics a gut hormone to lower blood sugar and aid weight loss — could significantly cut dementia risk ...
Diabetes drug semaglutide linked to reduced risk of dementia in type 2 diabetes patients Effects strongest in women and older adults, according to study of 1.7 million medical records Findings ...